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Objectives: To evaluate the clinical practice of non-muscle invasive bladder cancer 
(NMIBC) treatment in Brazil in relation to international guidelines: Sociedade Brasilei-
ra de Urologia (SBU), European Association of Urology (EAU) and American Urological 
Association (AUA).
Materials and Methods: Cross-sectional study using questionnaires about urological 
practice on treatment of NMIBC during the 32nd Brazilian Congress of Urology. A total 
of 650 question forms were answered.
Results: There were 73% of complete answers (total of 476 question forms). In total, 
246 urologists (51.68%) lived in the southeast region and 310 (65.13%) treat 1 to 3 
cases of NMIBC per month.
Low risk cancer: Only 35 urologists (7.5%) apply the single intravesical dose of imme-
diate chemotherapy with Mitomicin C recommended by the above guidelines. Adjuvant 
therapy with BCG 2 to 4 weeks after TUR is used by 167 participants (35.1%) and 271 
urologists (56.9%) use only TUR.
High risk tumors: 397 urologists (83.4%) use adjuvant therapy, 375 (78.8%) use BCG 
2 to 4 weeks after TUR, of which 306 (64.3%) referred the use for at least one year. In-
travesical chemotherapy with Mitomicin C (a controversial recommendation) was used 
by 22 urologists (4.6%). BCG dose raised a lot of discrepancies. Induction doses of 40, 
80 and 120mg were referred by 105 (22%), 193 (40.4%) and 54 (11.3%) respectively. 
Maintenance doses of 40, 80 and 120mg were referred by 190 (48.7%), 144 (37.0%) and 
32 (8.2%) urologists, respectively. Schemes of administration were also varied and the 
one cited by SWOG protocol was the most used: 142 (29.8%).
Conclusion: SBU, EAU and AUA guidelines are partially respected by Brazilian uro-
logists, particularly in low risk tumors. In high risk tumors, concordance rates are 
comparable to international data. Further studies are necessary to fully understand the 
reasons of such disagreement.
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INTRODuCTION
Bladder tumor is the seventh most com-
mon cancer in males and 17th in females. It 
affects approximately 110.000 men and 70.000 
women every year in the World. During 2012, 
38.200 and 17.000 deaths were registered due 
to BC in Europe and USA, respectively (1, 2). 
According to data from the National Cancer Ins-
titute of Brazil, there were 8,940 new cases in 
2014 (6.750 men and 2.190 women in the coun-
try (3).
Around 75% of bladder tumors are non-
-muscle invasive (NMSBC–pTa, pTis or PT1), 
which evolve differently and need adequate 
classification and treatment (1-3).
NMIBC treatment is standardized by the 
Brazilian Society of Urology (SBU), European 
Association of Urology (EAU) and American 
Urological Association (AUA). There are specific 
guidelines that show evidence that their use can 
improve survival rate of treated patients (4-7). 
However, daily practice may not correspond to 
what is recommended, mainly in Brazil, where 
there are no studies about this subject.
The present study was designed to 
analyze Brazilian urologist’s ongoing practice 
in relation to NMIBC and to compare them to 
SBU, EUA and AUA guidelines (Table-1) in or-
der to appoint differences between theory and 
practice in Brazilian hospitals and clinics.
MaTERIals aND METHODs
This cross-sectional study was performed 
during the 32nd Brazilian Congress of Urology. 
A total of 650 questionnaires were given to uro-
logists and 476 completed them (73%) regarding 
their experience and actions on NMIBC of low risk 
(single tumor, <3cm and low histological grade) 
and high risk (T1 or high grade or carcinoma in 
situ) submitted to transurethral resection in the 
last year (4).
Questionnaires contained two parts. First 
part had questions about demographic data: state 
where the physician works, local of practice, num-
ber of patients attended and treated each month. 
Second part comprised questions about treatment 
of NMIBC according to classification (low and 
high risk), use of intravesical therapy, drug used 
(chemotherapy, BCG, other), induction and main-
tenance doses, follow-up, use of new transurethral 
resection (re-TUR), etc.
All question forms were included in the 
study, even those incomplete, comprising 476 uro-
logists.
Results were analyzed in terms of percen-
tage of total answered forms.
Table 1 - Main International guidelines on NMIbC.
Classification EAU guideline AUA guideline
Low risk TUR
-Single dose of intravesical chemotherapy
TUR
-Single dose of intravesical chemotherapy 
(recommended)
Intermediate risk TUR
-Single dose of intravesical chemotherapy followed by:
1–BCG with maintenance for at least 1 year (level A)
2–Intravesical chemotherapy for 6-12 months (level B)
TUR
-Induction with BCG or Mitomicin 
(recommended)
-Maintenance with BCG or Mitomicin (option)
High risk TUR (re-TUR after 4-6 weeks)
-Single dose of intravesical chemotherapy followed by:
1-BCG with maintenance for at least 1 year (level A)
-Cystectomy may be considered for patients with high risk 
of progression (level C) or in cases with failure of BCG 
treatment (level B)
TUR (re-TUR after 4-6 weeks)
-Induction and maintenance with BCG 
(recommended)
-Cystectomy (option)
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REsulTs
Most participants lived in southeast region 
of Brazil (246 urologists, 51.68%) and 85.3% were 
from private practice, but not exclusive. 151 urolo-
gists worked in teaching facilities (31.7%) and 325 
(68.3%) had no relation to teaching institutions 
(Table-2). In view of the great number of answers 
regarding simultaneous practice in public, private 
and teaching institutions, it was not possible to 
stablish a correlation between adopted treatments 
and workplace.
In relation to experience, 310 (65.13%) 
urologists treated a media of 1 to 3 cases of NMI-
BC per month (12-36 cases per year), reflecting an 
adequate experience.
In relation to treatment of low risk patients, 
only 35 urologists (7.5%) followed the guidelines 
of BSU, EAU and AUA, performing TUR followed 
by a single immediate dose of intravesical chemo-
therapy with Mitomicin C (4-7); 271 (56.9%) did 
not use adjuvant therapy, only TUR and 167 (35%) 
performed TUR+intravesical BCG 2 to 4 weeks af-
ter TUR, totaling 91.9% of divergent treatments in 
relation to guidelines (Figure-1).
Among patients with high risk tumors, 
375 (78.8%) urologists performed TUR followed 
by adjuvant therapy with BCG 2 to 4 weeks af-
ter; however, 360 (75.6%) confirmed the use of 
the maintenance dose. Still, 22 (4.6%) participants 
Table 2 - Characteristics of urological Practice.
WHERE DO YOU WORK? TOTAL TOTAL
Private practice 406 85.3%
Private hospital 279 58.6%
Public hospital 163 34.2%
General or community hospital 
(noteaching)
162 34.0%
University or school hospital 151 31.7%
Cancer treatment center 57 12.0%
Other 31 6.5%
Figure 1 - Treatment of low risk tumors. 
performed immediate intravesical chemotherapy 
with Mitomicin C following TUR, although being 
a controversial recommendation of the guidelines 
(4-7) (Table-3).
Induction was employed by 300 (63.0%) 
urologists who used doses of 40, 80 and 120mg 
(105–22.1%, 193–40.5% and 54–11.3% partici-
pants, respectively). Induction time was also he-
Table 3 -  Treatment of high risk tumors.
Which is your standard treatment for 
high risk NMIBC tumors?
Total Total (%)
TUR+intravesical BCG 2 to 4 weeks 
after TUR
375 78.8%
Re-TUR 322 67.6%
Radical cystectomy 46 9.7%
TUR+immediate single dose of 
intravesical chemotherapy (Mitomicin 
C)
22 4.6%
Neoadjuvant chemotherapy followed by 
surgical resection
17 3.6%
Only TUR 10 2.1%
Others 6 1.3%
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terogeneous: 4 weeks–28 (5.9%), 6 weeks–320 
(67.2%) and 8 weeks–101 (21.2%).
Maintenance doses were used by 360 
urologists (75.6%). The used dose of 40, 80 and 
120mg was employed by 190 (39.9%), 144 (37.8%) 
and 32 (6.7%) urologists respectively.
In relation to interval, the answers were: 
weekly during 3 weeks on months 3, 6, 12, 18, 24, 
30 and 36 (SWOG protocol)–142 (29.8%); monthly 
during 1 year– 35 (28.4%); monthly during 2 ye-
ars–25 (5.3%) (Table-4).
These data reveal that, when BCG is used, 
there is a large variation regarding application re-
gimen and at least 306 participants (64.3%) main-
tain the treatment for at least one year, according 
to what is recommended by EAU guidelines for 
the treatment of high risk bladder tumor. In this 
respect, there was a 64.3% of accordance rate to 
the referred guideline.
A new TUR (re-TUR) for high risk patients 
was performed by 322 participants (67.6%) and 
41 (29.6%) did not perform it, reflecting the great 
number of urologists that do not follow the men-
tioned guidelines. Among those who performed 
re-TUR, 220 (46.2%), it was carried out 30 to 45 
days following initial TUR, while 71 (14.9%) after 
46 to 90 days after.
Table 4 - Maintenance regimens of bCg.
When you use maintenance therapy, how many doses are employed, in which interval and 
for how long?
Total (N) Total (%)
Weekly for 3 weeks in months 3, 6, 12, 18, 24, 30 e 36 142 29.8%
Monthly for 1 year 135 28.4%
Monthly for 2 years 25 5.3%
Monthly for 6 months 5 1.1%
Weekly for 3 weeks in months 3.6 and 12 1 0.2%
Twice every 3 or 4 months 1 0.2%
Monthly, continuous 1 0.2%
Weekly for 3 weeks in months 6 and 12 1 0.2%
Weekly for 6 months 1 0.2%
Others 75 15.8%
Did not answered 89 18.7%
Most used strains of BCG included More-
au and Connaught (282–59.3% and 125–26.3%, 
respectively). Besides, the own patient bought the 
vaccine without reimbursement, according to 204 
(42.9%) participants.
In cases where BCG treatment failed, 152 
(31.9%) urologists performed a new intravesical 
treatment with BCG, 115 (24.2%) used intravesi-
cal Mitomicin C and 11 (23.3%) performed radi-
cal cystectomy (recommended treatment by BSU, 
EAU and AUA guidelines in that situation). This 
data points out that 67.8% of participants do not 
follow the recommendations of the main guideli-
nes for BCG-failed patients (4-7).
DIsCussION
Guidelines are important orientations for 
medical practice, particularly in diseases where 
the level of evidence is not high enough to avoid 
questioning. They gather the highest level of evi-
dences so far available to that particular disease. 
So, it would be reasonable to expect a great level 
of accordance between medical practice and gui-
delines. However, in the present study, we obser-
ved great disparity between the proposed guide-
lines (SBU, EAU and AUA) (4-7) and the current 
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practice of Brazilian urologists, according to the 
questionnaires answers.
Treatment of low risk NMIBC showed the 
lower compliance of guidelines and only 7.5% of 
participants followed the recommended treatment 
(TUR followed by intravesical chemotherapy).
A meta-analysis of 1.476 patients showed 
a reduction of 11.7% of recurrence rates of BC tre-
ated with TUR+immediate instillation of Mitomi-
cin C compared to those treated only with TUR (8). 
In spite of this benefit, in our study Mitomicin C 
is rarely used by Brazilian urologists as adjuvant 
therapy of low risk NMIBC.
Another interesting fact relates to the sig-
nificant number of participants (35%) that used a 
dose of BCG 2 weeks after TUR for low risk pa-
tients. This practice is still controversial in litera-
ture, since meta-analysis showed benefits of BCG 
therapy in recurrence rates only for patients with 
high risk tumors (9). However, this is not an ab-
solute fact, since there are at least two other me-
ta-analysis that showed superiority of BCG over 
Mitomicin C in all high risk groups (10, 11). This 
blurred fact may explain the high use of BCH for 
low risk patients in this study.
Our study did not analyze patients with 
intermediate risk. Witjes et al. (12) observed the 
use of intravesical chemotherapy in only 29.4% of 
patients with intermediate risk disease but did not 
analyze low risk patients.
The treatment of high risk bladder tumors 
showed a good accordance to the guidelines: 
83.4% use adjuvant therapy, 4;6% use Mitomicin 
C, 78.8% use BCG and among these 75.6% use 
maintenance doses, and also 64.3% use BCG for at 
least 1 year, in accordance to the guidelines.
The rate of use of BCG for at least one year 
in North American and European studies (12-16) 
varies from 39.8% to 78% in patients with high 
risk tumors.
An North American study (150 with 494 
questionnaires available) showed a 89.7% of use 
of adjuvant intravesical therapy for high risk tu-
mors, and 87.3% used BCG, reflecting a global use 
of BCG of 78%. Another epidemiological study 
from Spain (16) analyzed 2.476 cases of BC being 
76.7% NMIBC, with a global rate of BCG use of 
39.8%. Anyway, Brazilian rates of compliance of 
guidelines are comparable to international series.
Isolated TUR was used by 10 participants 
(2.1%); this number is considerably inferior to that 
referred by a study performed in European and 
North American centers, where monotherapy with 
TUR was used by 9% (12).
Our study detailed the regimen of BCG ad-
ministration whenever indicated. There was a gre-
at variability regarding dose, application interval 
and total duration of treatment.
According to the guidelines, until now, the 
evidences show that there is no ideal dose and a 
reduced one does not lower side effects. However, 
the distribution of doses probably is based on the 
concern regarding BCG side effects.
The regimen of BCG use showed a great 
variation during induction and maintenance. Se-
veral regimens were cited by urologists, including 
never described regimens. However, it is possible 
to verify that the SWOG protocol was the most 
used for maintenance (29.8%), what is in accor-
dance to previously described (12, 15).
Guidelines vary in relation to the best regi-
men to be used; AUA guidelines suggest the use of 
a standard dose in SWOG regimen (17) for 3 years 
and EUA guidelines recommend maintenance for 
at least one year. AUA guidelines are based on a 
trial with 1.355 patients that used a standard dose 
and a reduced dose for maintenance during 1 to 3 
years with better rates of prevention of recurrence 
for the 3 year regimen with standard dose, althou-
gh it was not observed no difference in relation to 
risk of progression and overall survival (18, 19).
BCG strains are different in relation to 
phenotype, antigenicity and immunogenic activi-
ty, that may influence toxicity, tumor action and 
clinical efficacy. There are only a few studies that 
compared effectiveness and collateral effects of 
different strains, but those used in Brazil are the 
most common used worldwide (20-22).
Rate of Re-TUR in our study were nota-
bly superior in relation to two major international 
studies (15, 16), where rates varied from 10.4% to 
28%. We registered 67.7% of re-TUR.
Following BCG failure, only 23.3% (n=11) 
indicated cystectomy and not followed interna-
tional guidelines. Future studies should address 
criteria for recurrence, failure and intolerance of 
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BCG. Among these, early failure during intrave-
sical treatment reflects a more aggressive disease, 
justifying precocious cystectomy, while long term 
recurrence and intolerance are alternatively trea-
ted rather than with cystectomy, what could re-
flect our results.
Our data have never been published and 
there are very few studies in Brazilian literature. 
The lack of compliance and use of different regi-
mens other than the European and North Ameri-
can guidelines reaffirm the complexity and diver-
sity of NMIBC treatment (12, 15).
Limitations of the study include the num-
ber of urologists that refrained from answering 
the questionnaire and the fact that it was realized 
during the Brazilian Congress of Urology, with a 
potential bias of selection of professionals who 
tend to recycle and update their knowledge more 
frequently. Also, regional comparisons were not 
made, there was no correlation of data with de-
mographics, evaluation of intermediate tumors 
was not addressed, pathological data were not re-
viewed and the factors that influenced treatment 
were not investigated (lack of access to ideal tre-
atment, money issues, patient choice, urologist’s 
preferences, etc).
CONClusIONs
There is not a significant compliance of 
Brazilian urologists to BSU, EAU and AUA gui-
delines, particularly in low risk NMIBC. Further 
studies are necessary to fully understand the rea-
sons for such discrepancy. The results are similar 
to those of Europe and USA, but with particular 
aspects.
CONClusIONs
SBU = Sociedade Brasileira de Urologia
EAU = European Association of Urology
AUA = American Urological Association
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